scholarly journals Association of the G-174C Variant in the Interleukin-6 Promoter Region With Bone Loss and Fracture Risk in Older Women

2004 ◽  
Vol 19 (10) ◽  
pp. 1612-1618 ◽  
Author(s):  
Susan P Moffett ◽  
Joseph M Zmuda ◽  
Jane A Cauley ◽  
Katie L Stone ◽  
Michael C Nevitt ◽  
...  
Keyword(s):  
Bone Loss ◽  
Fracture Risk ◽  
Older Women ◽  
Interleukin 6 ◽  
Promoter Region

Intentional and Unintentional Weight Loss Increase Bone Loss and Hip Fracture Risk in Older Women

2003 ◽  
Vol 51 (12) ◽  
pp. 1740-1747 ◽  
Author(s):  
Kristine E. Ensrud ◽  
Susan K. Ewing ◽  
Katie L. Stone ◽  
Jane A. Cauley ◽  
Paula J. Bowman ◽  
...  
Keyword(s):  
Weight Loss ◽  
Hip Fracture ◽  
Bone Loss ◽  
Fracture Risk ◽  
Older Women ◽  
Unintentional Weight Loss ◽  
Hip Fracture Risk

Ten Years of Very Infrequent Zoledronate Therapy in Older Women: An Open-Label Extension of a Randomized Trial

2020 ◽  
Vol 105 (4) ◽  
pp. e1641-e1647 ◽  
Author(s):  
Andrew Grey ◽  
Anne Horne ◽  
Greg Gamble ◽  
Borislav Mihov ◽  
Ian R Reid ◽  
...  
Keyword(s):  
Bone Loss ◽  
Bone Turnover ◽  
Fracture Risk ◽  
Older Women ◽  
Academic Research ◽  
Mineral Density ◽  
Open Label ◽  
Original Cohort ◽  
Optimal Dosing ◽  
Open Label Extension

Abstract Context Intravenous zoledronate prevents bone loss and reduces fracture risk in older adults but the optimal dosing strategy required to achieve each outcome is not known. Objective To assess the effect of very infrequent zoledronate therapy on bone mineral density (BMD) and markers of bone turnover. Design and participants An average of 5.5 years after randomization to either a single dose of 5 mg of zoledronateor placebo, 33 of the original cohort of 50 older women with osteopenia entered a 5-year open-label extension study. Setting Academic research center Intervention A 5-mg dose of intravenous zoledronate was administered to all participants. Main outcome measures BMD and bone turnover were measured annually, generating data over almost 11 years in women who received 5 mg of zoledronate at 0 and 5.5 years (ZZ, n = 16), or placebo at baseline and 5 mg of zoledronate at 5.5 years (PZ, n = 17). Results After redosing, BMD in ZZ remained stable, while BMD in PZ increased. At 11 years, changes from baseline BMD in ZZ and PZ were 3.8% (95% confidence interval (CI) 1.1,6.5) and 2.9% (0.3,5.5) at the lumbar spine (P = .61), 0.9% (–1.7,3.5) and –2.8% (–5.3,–0.3) at the total hip (P = .006), and 0.4% (–0.8,1.6) and –0.4% (–1.3,0.5) at the total body (P = .14). Bone turnover markers were similar in the PZ and ZZ groups throughout the 5 years after redosing. Conclusions These results suggest that zoledronate 5 mg administered at a 5.5-year interval prevents bone loss over almost 11 years. Clinical trials to investigate whether very infrequent treatment with zoledronate reduces fracture risk are justified.

Investigate Bone Loss in Older Women on AEDs

2005 ◽  
Vol 38 (8) ◽  
pp. 23
Author(s):  
BRUCE JANCIN
Keyword(s):  
Bone Loss ◽  
Older Women

Body composition and hip fracture risk in older women: A prospective study

1996 ◽  
Vol 6 (S1) ◽  
pp. 132-132
Author(s):  
K. E. Ensrud ◽  
R. C. Lipschutz ◽  
J. A. Cauley ◽  
M. C. Nevitt ◽  
S. R. Cummings ◽  
...  
Keyword(s):  
Body Composition ◽  
Hip Fracture ◽  
Prospective Study ◽  
Fracture Risk ◽  
Older Women ◽  
Hip Fracture Risk ◽  
A Prospective Study

scholarly journals WHO absolute fracture risk models (FRAX): Do clinical risk factors improve fracture prediction in older women without osteoporosis?

2011 ◽  
Vol 26 (8) ◽  
pp. 1774-1782 ◽  
Author(s):  
Teresa A Hillier ◽  
Jane A Cauley ◽  
Joanne H Rizzo ◽  
Kathryn L Pedula ◽  
Kristine E Ensrud ◽  
...  
Keyword(s):  
Risk Factors ◽  
Fracture Risk ◽  
Older Women ◽  
Fracture Prediction ◽  
Clinical Risk Factors ◽  
Risk Models ◽  
Clinical Risk

scholarly journals Pharmacologic treatment of osteoporosis – 2011

2011 ◽  
Vol 152 (33) ◽  
pp. 1320-1326 ◽  
Author(s):  
Péter Lakatos
Keyword(s):  
Bone Loss ◽  
Fracture Risk ◽  
Hormone Replacement ◽  
Treatment Options ◽  
Osteoporotic Fractures ◽  
Cost Effective ◽  
Similar Efficacy ◽  
High Fracture ◽  
Efficient Treatment ◽  
Treatment Of Osteoporosis

Osteoporosis affects approximately 9% of the population in Hungary resulting in about 100 000 osteoporotic fractures annually. Thirty-five percent of patients with hip fractures due to osteoporosis will die within 1 year. Direct costs of osteoporosis exceed 25 billion forints per year. Apparently, cost-effective reduction of bone loss and consequent fracture risk will add up to not only financial savings but improvement in quality of life, as well. A number of pharmacological modalities are available for this purpose. The mainstay of the treatment of osteoporosis is the bisphosphonate group that includes effective anti-resorptive compounds mitigating bone loss and fragility. The recently registered denosumab exhibits similar efficacy by neutralizing RANK ligand, however, marked differences can be observed between the two drug classes. Strontium has a unique mechanism of action by rebalancing bone turnover, and thus, providing an efficient treatment option for the not fast bone losers who are at high fracture risk. The purely anabolic teriparatide is available for the extremely severe osteoporotic patients and for those who do not respond to other types of therapy. Older treatment options such as hormone replacement therapy, raloxifene, tibolone or calcitonin may also have a restricted place in the management of osteoporosis. Orv. Hetil., 2011, 152, 1320–1326.

Sign in / Sign up

Export Citation Format

Share Document